orziloben

Orziloben (NST-6179) is a synthetic, structurally engineered fatty acid (SEFA) analogue developed by NorthSea Therapeutics for the treatment of intestinal failure-associated liver disease (IFALD). As a medium-chain fatty acid derivative, it is designed to target metabolic and inflammatory pathways in the liver that are disrupted during long-term parenteral nutrition. Orziloben acts primarily as an agonist of the peroxisome proliferator-activated receptor alpha (PPARα), promoting fatty acid oxidation and reducing hepatic steatosis and inflammation. It is currently being evaluated in Phase 2 clinical trials as an oral therapy for adult patients with IFALD, a condition characterized by liver injury resulting from the lack of enteral nutrition and the components of parenteral nutrition.

Other names

orziloben